rBIO utilizes a proprietary recombinant expression platform based on synthetic biology to manufacture therapeutic polypeptides, starting with insulin. This scalable biosimilar program aims to significantly increase yields and reduce the cost of essential biologic drugs. The company focuses on domestic biomanufacturing to enhance the resilience and security of the U.S. pharmaceutical supply chain.
Funding
$60K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The majority of insulin production is concentrated overseas, creating vulnerabilities in the domestic supply chain. Recent shifts and discontinuations by manufacturers pose risks to patients dependent on specific insulin formulations.
Solution
rBIO is developing a biosimilar insulin, R-biolin, utilizing a proprietary recombinant expression platform designed for scalable and cost-effective biomanufacturing. This synthetic biology approach aims to increase insulin yields and reduce production costs by an estimated 30%. By focusing on domestic production, rBIO seeks to enhance the resilience of the pharmaceutical supply chain for essential biologic drugs. The platform leverages advanced microbial engineering to express therapeutic polypeptides, offering a faster, more adaptable alternative to legacy production methods.
Target Audience
The primary target audience includes individuals and entities within the pharmaceutical and healthcare sectors seeking more affordable and reliably sourced insulin, as well as those concerned with domestic pharmaceutical manufacturing capabilities.
Features
- Proprietary recombinant expression platform for therapeutic polypeptide manufacturing.
- Development of R-biolin, a biosimilar insulin candidate demonstrating bioequivalence to Novolin® R in preclinical studies.
- Synthetic biology approach utilizing reprogrammed microorganisms for protein expression.
- Continuous-fermentation process designed for increased yields and reduced cost of goods.
- Scalable manufacturing capability targeting several metric tons per year.
- IND-enabling studies underway for first-in-human trials.
- Focus on domestic biomanufacturing to strengthen pharmaceutical supply chains.